Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list / contract price is equivalent to or lower than the WPAS price.